[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients].
After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy. This is demonstrated in a multivariate analysis using the Cox model on a group of 469 patients who have been intraoperatively randomized to receive either intraportal chemotherapy for 7 days or no further treatment. The transfused patients with chemotherapy and those receiving neither transfusions nor chemotherapy had a relative risk of recurrence and death situated in between the two groups mentioned above, not statistically different from either of them. In the setting of this study, 7 days postoperative intraportal chemotherapy seems particularly effective in the non-transfused patients.
Harder
F
F
Departement Chirurgie, Universität, Kantonsspital Basel.
Laffer
U
U
Berres
M
M
Jäggi
P
P
Metzger
U
U
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001803:Blood Transfusion; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local / Q000401:mortality; D011183:Postoperative Complications / Q000401:mortality; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D015996:Survival Rate
D008937:Mitomycins; D016685:Mitomycin; D005472:Fluorouracil
Nach kurativer Resektion colorectaler Carcinome wirkt die portale Chemotherapie vor allem beim nicht-bluttransfundierten Patienten.